Veracyte, Inc. — Company profile
Healthcare · Diagnostics & Research · United States
Last price 50.01 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.02B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Details
| Name | Veracyte, Inc. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 755 |
| Founded | 2006 |
| Ipo Date | 2013-10-30 |
| Ceo | Marc Stapley |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92337F1075 |
| Cusip | 92337F107 |
| Cik | 0001384101 |
| Sic | 8071 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Marc A. Stapley | Chief Executive Officer and Director |
| Rebecca Chambers | Executive Vice President and Chief Financial Officer |
| Dr. Phillip G. Febbo M.D. | Chief Scientific and Medical Officer |
| Annie McGuire | Executive Vice President, General Counsel and Head of Market Access |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations |
| Jonathan Wygant | Vice President and Chief Accounting Officer |
| Dr. Kevin Richard Haas Ph.D. | Chief Development and Technology Officer |
| Steven French | Senior Vice President and Chief Information Officer |
| Kelly Gura | Director of Investor Relations |
Contact
| Address | 6000 Shoreline Court, Suite 300, South San Francisco, California 94080, United States |
| Phone | 650 243 6300 |
| Website | https://www.veracyte.com |